PortfoliosLab logoPortfoliosLab logo
CNCR vs. SPAQ
Performance
Return for Risk
Dividends
Drawdowns
Volatility

Performance

CNCR vs. SPAQ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Horizon Kinetics SPAC Active ETF (SPAQ). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CNCR vs. SPAQ - Yearly Performance Comparison


Returns By Period


CNCR

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*

SPAQ

1D
0.09%
1M
-0.41%
YTD
0.14%
6M
1.74%
1Y
4.91%
3Y*
5.25%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


CNCR vs. SPAQ - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than SPAQ's 0.85% expense ratio.


Return for Risk

CNCR vs. SPAQ — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

SPAQ
SPAQ Risk / Return Rank: 3030
Overall Rank
SPAQ Sharpe Ratio Rank: 2828
Sharpe Ratio Rank
SPAQ Sortino Ratio Rank: 2727
Sortino Ratio Rank
SPAQ Omega Ratio Rank: 2929
Omega Ratio Rank
SPAQ Calmar Ratio Rank: 3333
Calmar Ratio Rank
SPAQ Martin Ratio Rank: 3434
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. SPAQ - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Horizon Kinetics SPAC Active ETF (SPAQ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

CNCR vs. SPAQ - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


CNCRSPAQDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.57

Sharpe Ratio (All Time)

Calculated using the full available price history

0.78

Dividends

CNCR vs. SPAQ - Dividend Comparison

CNCR has not paid dividends to shareholders, while SPAQ's dividend yield for the trailing twelve months is around 16.66%.


TTM202520242023
CNCR
Loncar Cancer Immunotherapy ETF
0.00%0.00%0.00%0.00%
SPAQ
Horizon Kinetics SPAC Active ETF
16.66%16.69%3.00%2.60%

Drawdowns

CNCR vs. SPAQ - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum SPAQ drawdown of -5.30%. Use the drawdown chart below to compare losses from any high point for CNCR and SPAQ.


Loading graphics...

Drawdown Indicators


CNCRSPAQDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-5.30%

+5.30%

Max Drawdown (1Y)

Largest decline over 1 year

-5.30%

Current Drawdown

Current decline from peak

0.00%

-1.89%

+1.89%

Average Drawdown

Average peak-to-trough decline

0.00%

-0.53%

+0.53%

Ulcer Index

Depth and duration of drawdowns from previous peaks

1.42%

Volatility

CNCR vs. SPAQ - Volatility Comparison


Loading graphics...

Volatility by Period


CNCRSPAQDifference

Volatility (1M)

Calculated over the trailing 1-month period

1.75%

Volatility (6M)

Calculated over the trailing 6-month period

6.21%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

8.59%

-8.59%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

7.04%

-7.04%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

7.04%

-7.04%